The Danish company is set to use only renewable electricity to run its global production facilities by 2020, after an investment of $70m in a 672-acre solar panel installation.
GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.
On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.
Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.
Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.
Using automated chain-of-custody systems can save study sponsors and CROs a minimum of $1.3m per clinical trial in operating costs, according to a recent report from Almac.
Catalent Pharma Solutions has opened its new, 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.
The Brazil-headquartered antibiotics company announces that it has invested in two new buildings, a few years after running into regulatory trouble due to non-compliance with cGMP.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
Sticking is one of the most common issues that is faced in the manufacture of tablets, and may become a more pressing issue once continuous manufacturing is broadly adopted, suggests I Holland’s R&D manager.
Small molecule manufacturing can result in product loss, as the materials manufactured come into contact with internal surfaces thereby impacting drying and creating disruptions in efficency and cost-effectivness.
The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.
C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.
WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.
Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.
There is a common and often unchallenged perception that manufacturing quality standards in pharmerging countries are worrisome, but Lee Newton of Lonza argues this is not the reality.
Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.
ACG announces plans to grow its Latin American presence with its newest capsule production plant in Brazil, as it continues to expand its facilities in Asia-Pacific and Europe.
Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.
Haselmeier to provide assembly, labeling, and packaging services for its drug-device combination products following recent permission given to Germany-site.
Clinical trial sites are challenged by fragmented financial processes, according to a new study by the Society of Clinical Research sites and Greenphire released this week at SCOPE 2019.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
Boehringer Ingelheim and IBM Canada are using blockchain technology for the first time in a clinical trial setting to test the technology’s trial management capabilities.
Sharp invests $650,000 in its IRT solution to ensure proper supply allocations to support clinical trials and reduce costly overproduction for sponsors.
People on the move in January include new CEOs at Lonza, Taconic, MaSTherCell, Pii, and Wasdell, among several other c-suite shakeups and new hires as the industry kicks off the New Year.